Showing results (321-330 of 537) with videos related to

Sort By:
Pageof 54
Headache|May 22, 2018
Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post-Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled TrialDavid W Dodick, Stewart J Tepper, Deborah I Friedman, et al.
Headache|June 26, 2020
Open-Label, Multi-Dose, Pilot Safety Study of Injection of OnabotulinumtoxinA Toward the Otic Ganglion for the Treatment of Intractable Chronic Cluster HeadacheJoan Crespi, Daniel Bratbak, David W Dodick, et al.
Mayo Clinic Proceedings|September 24, 2005
Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trialStephen D Silberstein, Stuart R Stark, Sylvia M Lucas, et al.
Cephalalgia : an International Journal of Headache|June 26, 2019
Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trialDavid W Dodick, Richard B Lipton, Stephen Silberstein, et al.
The Lancet. Neurology|August 16, 2014
Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled studyDavid W Dodick, Peter J Goadsby, Egilius L H Spierings, et al.
Headache|February 27, 2024
Blood pressure elevation in erenumab-treated patients with migraine: A retrospective real-world experienceNikita Chhabra, Carolyn Mead-Harvey, Christopher A Dodoo, et al.
Headache|November 20, 2018
The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Post-Hoc Analyses on the First 3 Weeks of TreatmentStephen D Silberstein, Alan M Rapoport, Pippa S Loupe, et al.
Cephalalgia : an International Journal of Headache|April 20, 2021
Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and IISusan Hutchinson, Stephen D Silberstein, Andrew M Blumenfeld, et al.
Headache|October 17, 2017
AVP-825 (Sumatriptan Nasal Powder) Reduces Nausea Compared to Sumatriptan Tablets: Results of the COMPASS Randomized Clinical TrialRichard B Lipton, James S McGinley, Kenneth J Shulman, et al.
Current Pain and Headache Reports|October 29, 2004
Prioritizing treatment attributes and their impact on selecting an oral triptan: results from the TRIPSTAR ProjectDavid W Dodick, Richard B Lipton, Michel D Ferrari, et al.
Pageof 54